{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:03:10Z","timestamp":1784836990970,"version":"3.55.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed antihypertensive agents. Although their cardiovascular and renal benefits are well established, uncertainty remains regarding their long-term associations with cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare cancer incidence among patients treated exclusively with ACEIs or ARBs in a large population-based cohort with long-term follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Design, setting, and participants<\/jats:title>\n                    <jats:p>Retrospective cohort study using electronic health records from Clalit Health Services, Israel\u2019s largest healthcare organization. The source population included hypertensive adults aged 40 years or older who were free of cancer on January 1, 2000 (n\u2009=\u20091,048,575). After applying eligibility criteria and excluding patients who switched between treatment groups or were non-compliant with therapy, the final analytic cohort included 346,405 exclusive ACEI users and 77,018 exclusive ARB users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Exclusive treatment with either ACEIs or ARBs. Cancer incidence analyses were conducted during an active follow-up period from 2002 through 2024, allowing for a two-year exposure window.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>The primary outcome was diagnosis of any cancer. Secondary outcomes included the ten most prevalent cancer types diagnosed during follow-up. Cancer incidence rates, odds ratios (ORs), age at diagnosis, and time from treatment initiation to cancer diagnosis were compared between treatment groups after adjustment for age, sex, and exposure duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec006\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During follow-up, overall cancer incidence differed between treatment groups. ACEI therapy was associated with lower overall odds of cancer than ARB therapy. Associations varied across specific cancer types, with lower odds observed among ACEI users for several common malignancies, whereas no meaningful difference was observed for leukemia. Differences in age at diagnosis and time to diagnosis were also observed between treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec007\">\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>In this large population-based cohort, long-term cancer risk differed between patients treated exclusively with ACEIs and those treated exclusively with ARBs. While the observational design precludes causal inference, the findings contribute to the ongoing evaluation of the long-term oncologic safety profiles of RAAS-modulating therapies. Further prospective and mechanistic studies are needed to clarify the biological basis and clinical significance of these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354248","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:11:08Z","timestamp":1784833868000},"page":"e0354248","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparative analysis of ACE Inhibitors and ARBs as cancer risk factors"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4665-6837","authenticated-orcid":true,"given":"Belle","family":"Tamir Brahms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Afek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8820-3202","authenticated-orcid":true,"given":"Martine","family":"Granek-Catarivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-5116","authenticated-orcid":true,"given":"Tzipi","family":"Hornik-Lurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"11","key":"pone.0354248.ref001","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"AJ George","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"36","key":"pone.0354248.ref002","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039496","article-title":"Cost-effectiveness of ace inhibitors versus ARBs in heart failure management","volume":"103","author":"C Elendu","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"pone.0354248.ref003","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.562","article-title":"Cardiorenal effects of dual blockade with ACE inhibitors and ARBs among people with CKD: emulation of a reference trial (ONTARGET) using CPRD","volume":"39","author":"PJ Baptiste","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"pone.0354248.ref004","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.mayocp.2022.11.017","article-title":"ACEI and ARB - Each Unique RAAS Inhibitors: The Importance of Impact on Inflammation","volume":"98","author":"MH Strauss","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"pone.0354248.ref005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/1389557033487944","article-title":"Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)","volume":"3","author":"KMK Swamy","year":"2003","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"pone.0354248.ref006","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11906-020-1021-0","article-title":"Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls","volume":"22","author":"AM Berrido","year":"2020","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"pone.0354248.ref007","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12094-020-02488-3","article-title":"Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics","volume":"23","author":"B Afsar","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"pone.0354248.ref008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"F Deshayes","year":"2005","journal-title":"Trends Endocrinol Metab"},{"issue":"9386","key":"pone.0354248.ref009","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"MA Pfeffer","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"pone.0354248.ref010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"I Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0354248.ref011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"S Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0354248.ref012","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","author":"Collaboration ARB Trialists","year":"2011","journal-title":"J Hypertens"},{"issue":"16","key":"pone.0354248.ref013","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer","volume":"123","author":"B Pasternak","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"pone.0354248.ref014","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jch.14187","article-title":"Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea","volume":"23","author":"M-H Jung","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"pone.0354248.ref015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"K Bhaskaran","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"pone.0354248.ref016","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study","volume":"74","author":"J Hallas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0354248.ref017","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"pone.0354248.ref018","author":"Sandoz Inc","year":"2018"},{"key":"pone.0354248.ref019","author":"Sciegen Pharmaceuticals Inc","year":"2018"},{"key":"pone.0354248.ref020","author":"Aurobindo Pharma USA Inc","year":"2019"},{"key":"pone.0354248.ref021","author":"Health Canada","year":"2021"},{"issue":"17","key":"pone.0354248.ref022","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025714","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: A systematic review and meta-analysis","volume":"100","author":"M Batais","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pone.0354248.ref023","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00432-020-03445-x","article-title":"Risk of lung cancer and renin-angiotensin blockade: a concise review","volume":"147","author":"T Rachow","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"pone.0354248.ref024","doi-asserted-by":"crossref","first-page":"18576","DOI":"10.1038\/s41598-021-97989-8","article-title":"Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea","volume":"11","author":"S-H Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0354248.ref025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41416-022-02029-5","article-title":"Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis","volume":"128","author":"Z Wu","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"pone.0354248.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263461","article-title":"Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials","volume":"17","author":"I Sipahi","year":"2022","journal-title":"PLoS ONE"},{"issue":"1","key":"pone.0354248.ref027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006687","article-title":"Use of ACE (Angiotensin-Converting Enzyme) Inhibitors and Risk of Lung Cancer: A Nationwide Nested Case-Control Study","volume":"14","author":"KB Kristensen","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"pone.0354248.ref028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/cancers12030747","article-title":"Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer-A Nationwide, Population-Based, Propensity Score-Matched Cohort Study","volume":"12","author":"S-Y Lin","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:11:30Z","timestamp":1784833890000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354248"}},"subtitle":[],"editor":[{"given":"James M","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354248","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}